Infectious diseases can be caused by a variety of organisms that are inclusive of bacteria, viruses, fungi, and parasites. Some infectious diseases are contagious and can be passed from person to person. Few of these infectious diseases are transmitted by the bites of insects or animals while few are also acquired by ingestion of contaminated water or food. Some of the common examples of infectious diseases are acquired immunodeficiency syndrome (AIDS), hepatitis B, tuberculosis (TB), and others. Increasing prevalence of the infectious diseases like TB, AIDS, and others across the globe is one of the major drivers for the growth of the market during the forecast period. In 2016, according to the Centers for Disease Control and Prevention, TB affected one-third of the world’s population. Moreover, it was estimated that 10.4 million people around the world were detected with TB disease and the disease led to 1.7 million, people globally. Additionally, according to the World Health Organisation, in 2016, 36.7 million people lived with HIV/AIDS and the disease caused 1.0 million deaths, globally. Besides this, increasing healthcare expenditures, growing awareness of the patients will further boost the market growth. However, low adoption of the treatment and low per capita healthcare expenditure in the developing economies may restrain the market growth during the forecast period.
The global infectious disease treatments market is expected to grow at an approximate CAGR of 7.1% during the forecast period.
Segmentation
The global infectious disease treatments market is segmented on the basis of type, treatment, and end users.
On the basis of the type, the market is segmented into viral diseases, bacterial diseases, and others. The viral diseases segment is sub-segmented into acquired immunodeficiency syndrome (AIDS), hepatitis B, hepatitis C, and others. The bacterial diseases segment is sub-segmented into tuberculosis (TB), bacterial meningitis, and others.
On the basis of the treatment, the market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs, anti-parasitic drugs, and others. The antibacterial drugs segment is sub-segmented into beta-lactams, quinolones, sulfonamides, tetracyclines, and others. The antifungal drugs segment is sub-segmented into azoles, pyrimidines, echinodians, polyenes, and others.
On the basis of application, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, research organization, retail pharmacies, and others.
Key players for global infectious disease treatments market
Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Novartis AG (Switzerland), Sanofi (France), Mylan N.V. (U.S.), and others are some of the key players for the global infectious disease treatments market.
Request Customization
Get a Sample
Get a Sample
Request Customization